The Future of Orphan Disease Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement

Questions: Discounts, Updates etc.

Pages: 128

Price (Single): $3500

Price (Departmental): $7000

Price (Company): $10500

Publication Date: 2009-12-31

Order Online Now

Name:
Email:
Company Name:
Telephone:
Licence Type:
Payment Method:

People that purchased this report also purchased:

Contact LeadDiscovery

If you have questions about this report
To find out if you qualify for a discount
Want a more up to date version
Can't find a report that meets your needs

Search all reports

Summary

The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global orphan diseases therapeutics market. The report analyzes the markets for orphan diseases therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, and price are forecast until 2015 for the key geographies as well as select therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis.

Scope

The scope of this report includes:

Annualized market data for the orphan diseases therapeutics market from 2000 to 2008, forecast forward to 2015

Analysis of the leading therapeutic segments. These include Fabry Disease, Pompe Disease and Mucopolysaccharidosis.

Analysis of the orphan diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan

Market characterization of the orphan diseases therapeutics market including market size, annual cost of therapy, and treatment usage patterns

Key drivers and barriers that have a significant impact on the market

Coverage of pipeline molecules in various phases of drug development

Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Genzyme Corporation, Novartis AG, Celgene Corporation, Orphan Europe, Pfizer Inc, Actelion Pharmaceuticals and Shire Plc.

Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global orphan diseases therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

Align product portfolio to the markets with high growth potential

Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth

Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety

Develop key strategic initiatives by understanding key focus areas of leading companies

Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Global Orphan Disease Market : Introduction

2.1 Disease Overview
- 2.1.1 The United States
- 2.1.2 Europe
- 2.1.3 Japan
2.2 Report Guidance
2.3 Market Overview

3 Global Orphan Disease Therapeutics Market : Market Characterization

3.1 Market Forecasts
3.2 Orphan Drugs by Disease Sectors
3.3 Usage Patterns
- 3.3.1 Diseased Population
- 3.3.2 Treatment Seeking Population
- 3.3.3 Diagnosis Population
- 3.3.4 Prescription Population
- 3.3.5 Therapeutic Usage Patterns
3.4 Geographical Distribution
- 3.4.1 Market Drivers
- 3.4.2 Market Restraints
3.5 Key Market Trends
- 3.5.1 Increase in Federal Funding
- 3.5.2 Product Pipeline
- 3.5.3 Regulatory trends – Current Pricing and Reimbursement Scenario

4 Global Fabry Disease Therapeutics Market

4.1 Market Overview
4.2 Market Forecasts
4.3 Average Cost of Therapy
4.4 Usage Patterns
- 4.4.1 Diseased Population
- 4.4.2 Treatment Seeking Population
- 4.4.3 Diagnosis Population
- 4.4.4 Prescription Population
- 4.4.5 Therapeutic Usage Patterns
4.5 Product Analysis
- 4.5.1 Fabryzyme
- 4.5.2 Replagal
4.6 Drug Pipeline Analysis

5 Global Pompe Disease Therapeutics Market

5.1 Market Overview
5.2 Market Forecasts
5.3 Average Cost of Therapy
5.4 Usage Patterns
- 5.4.1 Diseased Population
- 5.4.2 Treatment Seeking Population
- 5.4.3 Diagnosis Population
- 5.4.4 Prescription Population
- 5.4.5 Therapeutic Usage Patterns
5.5 Product Analysis
- 5.5.1 Myozyme
5.6 Pipeline

6 Global Mucopolysaccharidosis VI Disease Therapeutics Market

6.1 Market Overview
6.2 Market Forecasts
6.3 Average Cost of Therapy
6.4 Usage Patterns
- 6.4.1 Diseased Population
- 6.4.2 Treatment Seeking Population
- 6.4.3 Diagnosis Population
- 6.4.4 Prescription Population
- 6.4.5 Therapeutic Usage Patterns
6.5 Product Analysis
- 6.5.1 Naglazyme

7 The US Orphan Disease Therapeutics Market

7.1 Market Overview
7.2 Market Forecasts
7.3 Usage Patterns
- 7.3.1 Diseased Population
- 7.3.2 Treatment Seeking Population
- 7.3.3 Diagnosis Population
- 7.3.4 Prescription Population
- 7.3.5 Therapeutic Usage Patterns

8 Europe Orphan Disease Therapeutics Market

8.1 Market Overview
8.2 Market Forecasts
8.3 Usage Patterns
- 8.3.1 Diseased Population
- 8.3.2 Treatment Seeking Population
- 8.3.3 Diagnosis Population
- 8.3.4 Prescription Population
- 8.3.5 Therapeutic Usage Patterns

9 Japan Orpahn Disease Therapeutics Market

9.1 Market Overview
9.2 Market Forecasts
9.3 Usage Patterns
- 9.3.1 Diseased Population
- 9.3.2 Treatment Seeking Population
- 9.3.3 Diagnosis Population
- 9.3.4 Prescription Population
- 9.3.5 Therapeutic Usage Patterns

10 Global Orphan Disease Therapeutics Market : Competitive Landscape

10.1 Overview
10.2 Competitor Profiling
- 10.2.1 Genzyme Corporation
- 10.2.2 Celgene Corporation
- 10.2.3 Actelion Pharmaceuticals
- 10.2.4 Shire Pharmaceuticals
- 10.2.5 AstraZeneca
- 10.2.6 Boehringer Ingelheim
- 10.2.7 Bristol-Myers Squibb
- 10.2.8 GlaxoSmithKline (GSK)
- 10.2.9 Novartis
- 10.2.10 Pfizer
- 10.2.11 Eli Lilly
- 10.2.12 Sanofi Aventis
- 10.2.13 UCB Pharma
- 10.2.14 Wyeth

11 Pipeline Analysis

11.1 Autoimmune Disorders
- 11.1.1 Cellcept
- 11.1.2 Pirfenidone
- 11.1.3 Rituxan
11.2 Genetic Disorders
- 11.2.1 Denufosol tetrasodium inhalation solution(INS37217)
- 11.2.2 Bronchitol(Mannitol)
- 11.2.3 Catena (Idebenone)
11.3 Infectious Diseases
- 11.3.1 XP-28 (xepol)
11.4 Neurology
- 11.4.1 Cladribine
- 11.4.2 Clazosentan (Pivlaz®)
11.5 Respiratory Disorders
11.6 Transplantation
11.7 Cardiovascular Disorders
- 11.7.1 ISIS 301012(Mipomersen sodium)
11.8 Cancer
- 11.8.1 Avastin
- 11.8.2 Enzastaurin
- 11.8.3 Patupilone
- 11.8.4 Zactima
- 11.8.5 Genasense
- 11.8.6 Ipilimumab (MDX-010, MDX-101)
11.9 Blood Cancer
11.10 Skin Cancer
11.11 Other Disorders

12 Global Orphan Disease Therapeutics Market: Strategic Consolidations

12.1 Mergers and Acquisitions
- 12.1.1 Genzyme Corp. and Bioenvision, Inc.
- 12.1.2 ViroPharma and Lev Pharmaceuticals
- 12.1.3 Biovitrum and Swedish Orphan
- 12.1.4 Shire plc and Zymenex A/s
12.2 Licensing Agreements
- 12.2.1 Overview
- 12.2.2 Drug Discovery & Preclinical
- 12.2.3 Phase I
- 12.2.4 Phase I
- 12.2.5 Phase III
- 12.2.6 Approved

13 Appendix

13.1 Market Definitions
13.2 Key Support Data
13.3 Abbreviations
13.4 Research Methodology
- 13.4.1 Coverage
- 13.4.2 Secondary Research
- 13.4.3 Primary Research
- 13.4.4 Forecasts
13.5 Expert Panel Validation
13.6 Contact Us
13.7 Disclaimer

1.1 List of Tables

Table 1: Orphan Disease Therapeutics Market: Orphan Disease Prevalence, Europe, 2008
Table 2: Orphan Disease Therapeutics Market: Definition and Incentives for Orphan Drugs, 2008
Table 3: Orphan Disease Therapeutics Market, Global, Revenue Forecasts, 2000-2008
Table 4: Orphan Disease Therapeutics Market, Global, Revenue Forecasts, 2008-2015
Table 5: Orphan Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2008
Table 6: Orphan Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015
Table 7: Orphan Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2008
Table 8: Orphan Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015
Table 9: Orphan Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2008
Table 10: Orphan Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015
Table 11: Orphan Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2008
Table 12: Orphan Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015
Table 13: Orphan Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2008
Table 14: Orphan Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015
Table 15: Orphan Disease Therapeutics Market, Global, Market Drivers, 2009-2015
Table 16: Orphan Disease Therapeutics Market, Global, Market Restraints, 2009 - 2015
Table 17: Orphan Disease Therapeutics Market, Definition and Incentives for Orphan Drugs, 2008
Table 18: Fabry Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2008
Table 19: Fabry Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2008-2015
Table 20: Fabry Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2001-2008
Table 21: Fabry Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015
Table 22: Fabry Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2008
Table 23: Fabry Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015
Table 24: Fabry Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2008
Table 25: Fabry Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015
Table 26: Fabry Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2008
Table 27: Fabry Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015
Table 28: Fabry Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2001-2008
Table 29: Fabry Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015
Table 30: Fabry Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
Table 31: Pompe Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2015
Table 32: Pompe Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2005-2015
Table 33: Pompe Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2008
Table 34: Pompe Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015
Table 35: Pompe Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2008
Table 36: Pompe Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015
Table 37: Pompe Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2008
Table 38: Pompe Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015
Table 39: Pompe Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2005-2015
Table 40: Pompe Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2008
Table 41: Pompe Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015
Table 42: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
Table 43: Pompe Disease Therapeutics Market, Global, Myozyme Sales, 2008
Table 44: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2015
Table 45: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2005-2015
Table 46: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2008
Table 47: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015
Table 48: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2008
Table 49: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015
Table 50: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2008
Table 51: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015
Table 52: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2005-2015
Table 53: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008
Table 54: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Naglazyme Sales, 2008
Table 55: Orphan Disease Therapeutics Market, The US, Revenue Forecasts ($m), 2000-2008
Table 56: Orphan Disease Therapeutics Market, The US, Revenue Forecasts ($m), 2008-2015
Table 57: Orphan Disease Therapeutics Market, The US, Forecasts for Diseased Population, 2000-2008
Table 58: Orphan Disease Therapeutics Market, The US, Forecasts for Diseased Population, 2008-2015
Table 59: Orphan Disease Therapeutics Market, The US, Forecasts for Treatment Seeking Population, 2000-2008
Table 60: Orphan Disease Therapeutics Market, The US, Forecasts for Treatment Seeking Population, 2008-2015
Table 61: Orphan Disease Therapeutics Market, The US, Forecasts for Diagnosis Population, 2000-2008
Table 62: Orphan Disease Therapeutics Market, The US, Forecasts for Diagnosis Population, 2008-2015
Table 63: Orphan Disease Therapeutics Market, The US, Forecasts for Prescription Population, 2000-2008
Table 64: Orphan Disease Therapeutics Market, The US, Forecasts for Prescription Population, 2008-2015
Table 65: Orphan Disease Therapeutics Market, The US, Forecasts for Therapeutic Usage Patterns, 2000-2008
Table 66: Orphan Disease Therapeutics Market, The US, Forecasts for Therapeutic Usage Patterns, 2008-2015
Table 67: Orphan Disease Therapeutics Market, Europe, Revenue Forecasts ($m), 2000-2008
Table 68: Orphan Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2008-2015
Table 69: Orphan Disease Therapeutics Market, Europe, Forecasts for Diseased Population, 2000-2008
Table 70: Orphan Disease Therapeutics Market, Europe, Forecasts for Diseased Population, 2008-2015
Table 71: Orphan Disease Therapeutics Market, Europe, Forecasts for Treatment Seeking Population, 2000-2008
Table 72: Orphan Disease Therapeutics Market, Europe, Forecasts for Treatment Seeking Population, 2008-2015
Table 73: Orphan Disease Therapeutics Market, Europe, Forecasts for Diagnosis Population, 2000-2008
Table 74: Orphan Disease Therapeutics Market, Europe, Forecasts for Diagnosis Population, 2008-2015
Table 75: Orphan Disease Therapeutics Market, Europe, Forecasts for Prescription Population, 2000-2008
Table 76: Orphan Disease Therapeutics Market, Europe, Forecasts for Prescription Population, 2008-2015
Table 77: Orphan Therapeutics Market, Europe, Forecasts for Therapeutic Usage Patterns, 2000-2015
Table 78: Orphan Therapeutics Market, Europe, Forecasts for Therapeutic Usage Patterns, 2000-2015
Table 79: Orphan Disease Therapeutics Market, Japan, Revenue Forecasts ($m), 2000-2015
Table 80: Orphan Disease Therapeutics Market, Japan, Revenue Forecasts ($m), 2008-2015
Table 81: Orphan Disease Therapeutics Market, Japan, Forecasts for Diseased Population, 2000-2008
Table 82: Orphan Disease Therapeutics Market, Japan, Forecasts for Diseased Population, 2008-2015
Table 83: Orphan Disease Therapeutics Market, Japan, Forecasts for Treatment Seeking Population, 2000-2008
Table 84: Orphan Disease Therapeutics Market, Japan, Forecasts for Treatment Seeking Population, 2008-2015
Table 85: Orphan Disease Therapeutics Market, Japan, Forecasts for Diagnosis Population, 2000-2008
Table 86: Orphan Disease Therapeutics Market, Japan, Forecasts for Diagnosis Population, 2008-2015
Table 87: Orphan Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2008
Table 88: Orphan Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015
Table 89: Orphan Disease Therapeutics Market, Japan, Forecasts for Therapeutic Usage Patterns, 2000-2008
Table 90: Orphan Disease Therapeutics Market, Japan, Forecasts for Therapeutic Usage Patterns, 2008-2015
Table 91: Orphan Disease Therapeutics Market, Global, Pipeline Analysis of Autoimmune Disorders, 2008
Table 92: Orphan Disease Therapeutics Market, Global, Pipeline Analysis of Genetic Disorders, 2008
Table 93: Orphan Disease Therapeutics Market, Global, Pipeline Analysis of Infectious Diseases, 2008
Table 94: Orphan Disease Therapeutics Market, Global, Pipeline Analysis of Neurology Disorders, 2008
Table 95: Orphan Disease Therapeutics Market, Global, Pipeline Analysis of Respiratory Disorders, 2008
Table 96: Orphan Disease Therapeutics Market, Global, Pipeline Analysis of Transplantation, 2008
Table 97: Orphan Disease Therapeutics Market, Global, Pipeline Analysis of Cardiovascular Disorders, 2008
Table 98: Orphan Disease Therapeutics Market, Global, Pipeline Analysis of Cancer, 2008
Table 99: Orphan Disease Therapeutics Market, Global, Pipeline Analysis of Blood Cancer, 2008
Table 100:Orphan Disease Therapeutics Market, Global, Pipeline Analysis of Skin Cancer, 2008
Table 101:Orphan Disease Therapeutics Market, Global, Pipeline Analysis of Autoimmune Disorders, 2008
Table 102:Orphan Disease Therapeutics Market, Global, Licensing Agreements for Drugs in the Discovery and Preclinical Stages, 2008
Table 103:Orphan Disease Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase I Stage, 2008
Table 104: Orphan Disease Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II Stages, 2008
Table 105: Orphan Disease Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III Stages, 2008
Table 106: Orphan Disease Therapeutics Market, Global, Licensing Agreements for Drugs in the Approved Stages, 2008

1.2 List of Figures

Figure 1: Orphan Disease Therapeutics Market, Global, Market Overview, 2008
Figure 2: Orphan Disease Therapeutics Market, Global, Revenue Forecasts ($bn), 2000-2015
Figure 3: Orphan Disease Therapeutics Market, The US, Orphan Drugs by Disease Sectors, 2008
Figure 4: Orphan Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015
Figure 5: Orphan Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015
Figure 6: Orphan Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015
Figure 7: Orphan Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015
Figure 8: Orphan Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015
Figure 9: Orphan Disease Therapeutics Market, Global, Geographical Distribution of Revenues ($bn), 2000-2015
Figure 10: Orphan Disease Therapeutics Market, Global, Geographical Comparison of Market Competition, 2008
Figure 11: Orphan Disease Therapeutics Market, Global, Market Indicators, 2008
Figure 12: Orphan Disease Therapeutics Market, The US, Approved Orphan Drugs, 20008-2009
Figure 13: Orphan Disease Therapeutics Market, The US and Europe, Designated Orphan Drugs, 2004-2018
Figure 14: Orphan Disease Therapeutics Market, Europe, Approved Orphan Drugs and Indications, 2008
Figure 15: Orphan Disease Therapeutics Market, Global, Key Market Events, 2008-2015
Figure 16: Orphan Disease Therapeutics Market, Global, Pricing of an Orphan Drug, 2008
Figure 17: Orphan Disease Therapeutics Market, Global, Prevalence and the Annual Cost of Therapy
Figure 18: Orphan Disease Therapeutics Market, Global, Price Control Measures on Orphan Drugs
Figure 19: Fabry Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2015
Figure 20: Fabry Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2001-2015
Figure 21: Fabry Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015
Figure 22: Fabry Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015
Figure 23: Fabry Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015
Figure 24: Fabry Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2001-2015
Figure 25: Fabry Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015
Figure 26: Fabry Disease Therapeutics Market, Global, Market Share of Major Therapeutic Drugs, 2008
Figure 27: Fabry Disease Therapeutics Market, Global, Historical Revenues of Major Drugs ($m), 2006-2008
Figure 28: Pompe Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2015
Figure 29: Pompe Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2005-2015
Figure 30: Pompe Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015
Figure 31: Pompe Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015
Figure 32: Pompe Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015
Figure 33: Pompe Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2005-2015
Figure 34: Pompe Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015
Figure 35: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Revenue Forecasts ($m), 2005-2015
Figure 36: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2005-2015
Figure 37: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015
Figure 38: Fabry Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015
Figure 39: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015
Figure 40: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2005-2015
Figure 41: Mucopolysaccharidosis VI Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015
Figure 42: Orphan Disease Therapeutics Market, The US, Revenue Forecasts ($bn), 2000-2015
Figure 43: Orphan Disease Therapeutics Market, The US, Forecasts for Diseased Population, 2000-2015
Figure 44: Orphan Disease Therapeutics Market, The US, Forecasts for Treatment Seeking Population, 2000-2015
Figure 45: Orphan Disease Therapeutics Market, The US, Forecasts for Diagnosis Population, 2000-2015
Figure 46: Orphan Disease Therapeutics Market, The US, Forecasts for Prescription Population, 2000-2015
Figure 47: Orphan Disease Therapeutics Market, The US, Forecasts for Therapeutic Usage Patterns, 2000-2015
Figure 48: Orphan Disease Therapeutics Market, EUrope, Revenue Forecasts ($bn), 2000-2015
Figure 49: Orphan Disease Therapeutics Market, Europe, Forecasts for Diseased Population, 2000-2015
Figure 50: Orphan Disease Therapeutics Market, Europe, Forecasts for Treatment Seeking Population, 2000-2015
Figure 51: Orphan Disease Therapeutics Market, Europe, Forecasts for Diagnosis Population, 2000-2015
Figure 52: Orphan Disease Therapeutics Market, Europe, Forecasts for Prescription Population, 2000-2015
Figure 53: Orphan Therapeutics Market, Europe, Forecasts for Therapeutic Usage Patterns, 2000-2015
Figure 54: Orphan Disease Therapeutics Market, Japan, Revenue Forecasts ($m), 2000-2015
Figure 55: Orphan Disease Therapeutics Market, Japan, Forecasts for Diseased Population, 2000-2015
Figure 56: Orphan Disease Therapeutics Market, Japan, Forecasts for Treatment Seeking Population, 2000-2015
Figure 57: Orphan Disease Therapeutics Market, Japan, Forecasts for Diagnosis Population, 2000-2015
Figure 58: Orphan Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015
Figure 59: Orphan Disease Therapeutics Market, Japan, Forecasts for Therapeutic Usage Patterns, 2000-2015
Figure 60: Orphan Disease Therapeutics Market, The US, Orphan Drug Indications, 2000-2008
Figure 61: Orphan Disease Therapeutics Market, Global, Sales Revenues of Orphan Drugs, 2008
Figure 62: Orphan Disease Therapeutics Market, Global, Pipeline Split by Disease Sectors, 2008
Figure 63: Orphan Disease Therapeutics Market, Global, Licensing Agreements Split by Disease Sectors, 2008
Figure 64: Orphan Disease Therapeutics Market, Global, Licensing Agreements Split by Clinical Trial Phase, 2008
Figure 65: Orphan Disease Therapeutics Market, Global, Licensing Agreements Split by Deal Size, 2008
Figure 66: Research Methodology
Figure 67: Research Market Forecasting Model

Other users found this report page using the following search terms: orphan disease disease orphan market therapeutics future fabrydiseasemarket xp28 xepol fabry forecast

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.

The Future of Orphan Disease Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement

Credit Card Details

Invoice Details

Table of Contents